文献速递临床免疫分子诊断

结直肠癌来源外泌体作为生物标志物的潜力

The potential of exosomes derived from colorectal cancer as a biomarker.
PubMed 文献 · Clin Chim Acta · 2018-09-06

研究以结直肠癌细胞、肾癌细胞和乳腺癌细胞培养上清分离外泌体,用Roche Cobas E601电化学发光免疫分析、western blot和流式细胞术检测外泌体肿瘤标志物。结果显示CK19在结直肠细胞来源外泌体中普遍表达,TAG72主要见于5-FU耐药结直肠癌细胞外泌体,CA125见于高转移结直肠癌细胞外泌体;肿瘤间质液与患者血浆来源外泌体CK19、TAG72、CA125水平不同。提示外泌体CK19与结直肠组织相关,富含TAG72的外泌体提示可能对5-氟尿嘧啶耐药,富含CA125的外泌体可能作为转移性结直肠癌标志物。

要点

  • 外泌体CK19与结直肠组织相关,可作为结直肠癌相关标志物。
  • 富含TAG72的外泌体提示结直肠癌患者可能对5-氟尿嘧啶耐药。
  • 富含CA125的外泌体可能作为转移性结直肠癌的标志物。

核心结论

  • 外泌体来源的CK19与结直肠组织相关,TAG72-rich外泌体提示可能对5-氟尿嘧啶耐药,CA125-rich外泌体可能作为转移性结直肠癌标志物。

研究设计与样本

  • 研究采用结直肠癌细胞、肾细胞癌细胞和乳腺癌细胞的培养上清分离外泌体,并用Roche Cobas E601全自动电化学发光免疫分析系统、western blot和流式细胞术分析外泌体肿瘤标志物。
  • 另检测肿瘤间质液来源外泌体与患者血浆来源外泌体中CK19、TAG72和CA125的水平。

主要发现

  • CK19在结直肠细胞来源的外泌体中普遍表达。
  • TAG72主要表达于5-FU耐药结直肠癌细胞来源的外泌体。
  • CA125主要表达于高转移结直肠癌细胞来源的外泌体。
  • 肿瘤间质液来源外泌体与患者血浆来源外泌体显示不同水平的CK19、TAG72和CA125。

关键数值与推荐

  • CK19在结直肠细胞来源外泌体中普遍表达。
  • TAG72主要表达于5-FU耐药结直肠癌细胞外泌体。
  • CA125主要表达于高转移结直肠癌细胞外泌体。

临床怎么用

  • 外泌体CK19、TAG72和CA125有望作为结直肠癌诊断与进展预测的无创临床工具。
  • 检测外泌体TAG72可能提示结直肠癌患者对5-氟尿嘧啶耐药。
  • 检测外泌体CA125可能提示结直肠癌转移。

局限性

  • 外泌体具有多样性和多来源性,给其作为临床生物标志物带来挑战。
  • 研究需解决外泌体的区分与分类问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Colorectal cancer (CRC) is one of the most frequent causes of cancer death. The diagnosis and treatment for metastatic CRC and patients with drug resistance remains poor. Cancer cells characteristically produce and release exosomes, which act as a new signal pattern in the occurrence and development of tumors. Circulating exosomes constitute promising biomarkers for early diagnosis of cancer patients. However, the potential of exosomes for clinical biomarker is hampered by their variousness and multi-sources. To this aim, we set out to solve the problem of discrimination and classification of exosomes. The cell culture supernatants of CRC cells, renal cell carcinoma cells and breast cancer cells were used for isolating exosomes. Then characteristic exosomal tumor markers were explored by Roche Cobas E601 fully automated electrochemiluminescence immunoassay systems, western blot and flow cytometry analysis. The results showed that CK19 was commonly expressed in exosomes derived from colorectal cells, TAG72 was mainly expressed in exosomes of 5-FU-resistant CRC cells and CA125 in those of high metastatic CRC cells. In addition, tumor interstitial fluid derived exosomes and patients' plasma derived exosomes showed different levels of CK19, TAG72 and CA125. Collectively, these data indicated that exosomes derived CK19 is correlated with colorectal tissue. TAG72-rich exosomes indicate that CRC patients might be resistant to 5-Fluorouraci. CA125-rich exosomes might be as metastatic CRC markers. These provide a good prospect for cell exosomes as novel, non-invasive clinical tool for diagnosing CRC and predicting its progression.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Xiao Y, Li Y, Yuan Y, et al. The potential of exosomes derived from colorectal cancer as a biomarker. Clin Chim Acta. 2018. PMID: 30194933. doi:10.1016/j.cca.2018.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。